|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
|
|
2
|
Singh D, Vignat J, Lorenzoni V, Eslahi M,
Ginsburg O, Lauby-Secretan B, Arbyn M, Basu P, Bray F and
Vaccarella S: Global estimates of incidence and mortality of
cervical cancer in 2020: A baseline analysis of the WHO global
cervical cancer elimination initiative. Lancet Glob Health.
11:e197–e206. 2023.
|
|
3
|
van Malenstein H, van Pelt J and Verslype
C: Molecular classification of hepatocellular carcinoma anno 2011.
Eur J Cancer. 47:1789–1797. 2011.
|
|
4
|
Park YN: Update on precursor and early
lesions of hepatocellular carcinomas. Arch Pathol Lab Med.
135:704–715. 2011.
|
|
5
|
Trevisani F, Cantarini MC, Wands JR and
Bernardi M: Recent advances in the natural history of
hepatocellular carcinoma. Carcinogenesis. 29:1299–1305. 2008.
|
|
6
|
Choi JY, Lee JM and Sirlin CB: CT and MR
imaging diagnosis and staging of hepatocellular carcinoma: Part I.
Development, growth, and spread: Key pathologic and imaging
aspects. Radiology. 272:635–654. 2014.
|
|
7
|
Komuta M: Histological heterogeneity of
primary liver cancers: Clinical relevance, diagnostic pitfalls and
the pathologist's role. Cancers (Basel). 13:28712021.
|
|
8
|
Berardi G, Igarashi K, Li CJ, Ozaki T,
Mishima K, Nakajima K, Honda M and Wakabayashi G: Parenchymal
sparing anatomical liver resections with full laparoscopic
approach: Description of technique and short-term results. Ann
Surg. 273:785–791. 2021.
|
|
9
|
Clavien PA, Lesurtel M, Bossuyt PM, Gores
GJ, Langer B and Perrier A; OLT for HCC Consensus Group:
Recommendations for liver transplantation for hepatocellular
carcinoma: An international consensus conference report. Lancet
Oncol. 13:e11–e22. 2012.
|
|
10
|
Pan T, Xie QK, Lv N, Li XS, Mu LW, Wu PH
and Zhao M: Percutaneous CT-guided radiofrequency ablation for
lymph node oligometastases from hepatocellular carcinoma: A
propensity score-matching analysis. Radiology. 282:259–270.
2017.
|
|
11
|
Cabibbo G, Enea M, Attanasio M, Bruix J,
Craxì A and Cammà C: A meta-analysis of survival rates of untreated
patients in randomized clinical trials of hepatocellular carcinoma.
Hepatology. 51:1274–1283. 2010.
|
|
12
|
Xing R, Gao J, Cui Q and Wang Q:
Strategies to improve the antitumor effect of immunotherapy for
hepatocellular carcinoma. Front Immunol. 12:7832362021.
|
|
13
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. New Engl J
Med. 359:378–390. 2008.
|
|
14
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018.
|
|
15
|
Reig M, Torres F, Rodriguez-Lope C, Forner
A, LLarch N, Rimola J, Darnell A, Ríos J, Ayuso C and Bruix J:
Early dermatologic adverse events predict better outcome in HCC
patients treated with sorafenib. J Hepatol. 61:318–324. 2014.
|
|
16
|
Chen S, Cao Q, Wen W and Wang H: Targeted
therapy for hepatocellular carcinoma: Challenges and opportunities.
Cancer Lett. 460:1–9. 2019.
|
|
17
|
Greten TF, Lai CW, Li G and
Staveley-O'Carroll KF: Targeted and immune-based therapies for
hepatocellular carcinoma. Gastroenterology. 156:510–524. 2019.
|
|
18
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
|
|
19
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018.
|
|
20
|
Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX,
Kim TY, Kudo M, Breder V, Merle P, Kaseb A, et al: Patient-reported
outcomes with atezolizumab plus bevacizumab versus sorafenib in
patients with unresectable hepatocellular carcinoma (IMbrave150):
An open-label, randomised, phase 3 trial. Lancet Oncol.
22:991–1001. 2021.
|
|
21
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022.
|
|
22
|
Kelley RK, Sangro B, Harris W, Ikeda M,
Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, et al: Safety,
efficacy, and pharmacodynamics of tremelimumab plus durvalumab for
patients with unresectable hepatocellular carcinoma: Randomized
expansion of a phase I/II study. J Clin Oncol. 39:2991–3001.
2021.
|
|
23
|
Giannini EG, Aglitti A, Borzio M, Gambato
M, Guarino M, Iavarone M, Lai Q, Levi Sandri GB, Melandro F,
Morisco F, et al: Overview of immune checkpoint inhibitors therapy
for hepatocellular carcinoma, and the ITA.LI.CA cohort derived
estimate of amenability rate to immune checkpoint inhibitors in
clinical practice. Cancers (Basel). 11:16892019.
|
|
24
|
Greten TF, Abou-Alfa GK, Cheng AL, Duffy
AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, et
al: Society for immunotherapy of cancer (SITC) clinical practice
guideline on immunotherapy for the treatment of hepatocellular
carcinoma. J Immunother Cancer. 9:e0027942021.
|
|
25
|
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron
AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, et al:
Phase Ib study of lenvatinib plus pembrolizumab in patients with
unresectable hepatocellular carcinoma. J Clin Oncol. 38:2960–2970.
2020.
|
|
26
|
Wang Z, Wang Y, Gao P and Ding J: Immune
checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer
Lett. 555:2160382023.
|
|
27
|
Dolladille C, Ederhy S, Sassier M, Cautela
J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF,
et al: Immune checkpoint inhibitor rechallenge after immune-related
adverse events in patients with cancer. JAMA Oncol. 6:865–871.
2020.
|
|
28
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018.
|
|
29
|
Nyiramana MM, Cho SB, Kim EJ, Kim MJ, Ryu
JH, Nam HJ, Kim NG, Park SH, Choi YJ, Kang SS, et al: Sea hare
hydrolysate-induced reduction of human non-small cell lung cancer
cell growth through regulation of macrophage polarization and
non-apoptotic regulated cell death pathways. Cancers (Basel).
12:7262020.
|
|
30
|
Gao R, Kalathur RKR, Coto-Llerena M, Ercan
C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD,
Christofori G and Tang F: YAP/TAZ and ATF4 drive resistance to
Sorafenib in hepatocellular carcinoma by preventing ferroptosis.
EMBO Mol Med. 13:e143512021.
|
|
31
|
Lai Y, Lu N, Luo S, Wang H and Zhang P: A
photoactivated sorafenib-ruthenium(II) prodrug for resistant
hepatocellular carcinoma therapy through ferroptosis and purine
metabolism disruption. J Med Chem. 65:13041–13051. 2022.
|
|
32
|
Rosenbaum SR, Wilski NA and Aplin AE:
Fueling the fire: Inflammatory forms of cell death and implications
for cancer immunotherapy. Cancer Discov. 11:266–281. 2021.
|
|
33
|
Hadian K and Stockwell BR: The therapeutic
potential of targeting regulated non-apoptotic cell death. Nat Rev
Drug Discov. 22:723–742. 2023.
|
|
34
|
Gao W, Wang X, Zhou Y, Wang X and Yu Y:
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor
immunotherapy. Signal Transduct Target Ther. 7:1962022.
|
|
35
|
Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao
W, Xu Z, Yang Y, Weng Q, Zhao Z, et al: Targeted xCT-mediated
ferroptosis and protumoral polarization of macrophages is effective
against HCC and enhances the efficacy of the anti-PD-1/L1 response.
Adv Sci (Weinh). 10:e22039732023.
|
|
36
|
Zheng Y, Wang Y, Lu Z, Wan J, Jiang L,
Song D, Wei C, Gao C, Shi G, Zhou J, et al: PGAM1 inhibition
promotes HCC ferroptosis and synergizes with anti-PD-1
immunotherapy. Adv Sci (Weinh). 10:e23019282023.
|
|
37
|
Meng J, Yang X, Huang J, Tuo Z, Hu Y, Liao
Z, Tian Y, Deng S, Deng Y, Zhou Z, et al: Ferroptosis-enhanced
immunotherapy with an injectable dextran-chitosan hydrogel for the
treatment of malignant ascites in hepatocellular carcinoma. Adv Sci
(Weinh). 10:e23005172023.
|
|
38
|
Wang H, Zhang B, Shang Y, Chen F, Fan Y
and Tan K: A novel risk score model based on pyroptosis-related
genes for predicting survival and immunogenic landscape in
hepatocellular carcinoma. Aging (Albany NY). 15:1412–1444.
2023.
|
|
39
|
Peng YL, Wang LX, Li MY, Liu LP and Li RS:
Construction and validation of a prognostic signature based on
necroptosis-related genes in hepatocellular carcinoma. PLoS One.
18:e2797442023.
|
|
40
|
Wang Y, Wang Y, Pan J, Gan L and Xue J:
Ferroptosis, necroptosis, and pyroptosis in cancer: Crucial cell
death types in radiotherapy and post-radiotherapy immune
activation. Radiother Oncol. 184:1096892023.
|
|
41
|
Hage C, Hoves S, Strauss L, Bissinger S,
Prinz Y, Pöschinger T, Kiessling F and Ries CH: Sorafenib induces
pyroptosis in macrophages and triggers natural killer cell-mediated
cytotoxicity against hepatocellular carcinoma. Hepatology.
70:1280–1297. 2019.
|
|
42
|
Li Y, Yang W, Zheng Y, Dai W, Ji J, Wu L,
Cheng Z, Zhang J, Li J, Xu X, et al: Targeting fatty acid synthase
modulates sensitivity of hepatocellular carcinoma to sorafenib via
ferroptosis. J Exp Clin Canc Res. 42:62023.
|
|
43
|
Bhosale PB, Abusaliya A, Kim HH, Ha SE,
Park MY, Jeong SH, Vetrivel P, Heo JD, Kim JA, Won CK, et al:
Apigetrin promotes TNFα-induced apoptosis, necroptosis, G2/M phase
cell cycle arrest, and ROS generation through inhibition of NF-κB
pathway in Hep3B liver cancer cells. Cells. 11:27342022.
|
|
44
|
Wang Q, Wang Y, Ding J, Wang C, Zhou X,
Gao W, Huang H, Shao F and Liu Z: A bioorthogonal system reveals
antitumour immune function of pyroptosis. Nature. 579:421–426.
2020.
|
|
45
|
Xu C, Sun S, Johnson T, Qi R, Zhang S,
Zhang J and Yang K: The glutathione peroxidase Gpx4 prevents lipid
peroxidation and ferroptosis to sustain Treg cell activation and
suppression of antitumor immunity. Cell Rep. 35:1092352021.
|
|
46
|
Wang W, Marinis JM, Beal AM, Savadkar S,
Wu Y, Khan M, Taunk PS, Wu N, Su W, Wu J, et al: RIP1 kinase drives
macrophage-mediated adaptive immune tolerance in pancreatic cancer.
Cancer Cell. 34:757–774.e7. 2018.
|
|
47
|
Lu Y, Chan YT, Tan HY, Zhang C, Guo W, Xu
Y, Sharma R, Chen ZS, Zheng YC, Wang N and Feng Y: Epigenetic
regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates
sorafenib resistance in human hepatocellular carcinoma. J Exp Clin
Cancer Res. 41:32022.
|
|
48
|
Liao Y, Yang Y, Pan D, Ding Y, Zhang H, Ye
Y, Li J and Zhao L: HSP90α mediates sorafenib resistance in human
hepatocellular carcinoma by necroptosis inhibition under hypoxia.
Cancers (Basel). 13:2432021.
|
|
49
|
Tang R, Xu J, Zhang B, Liu J, Liang C, Hua
J, Meng Q, Yu X and Shi S: Ferroptosis, necroptosis, and pyroptosis
in anticancer immunity. J Hematol Oncol. 13:1102020.
|
|
50
|
Aaes TL, Kaczmarek A, Delvaeye T, De
Craene B, De Koker S, Heyndrickx L, Delrue I, Taminau J, Wiernicki
B, De Groote P, et al: Vaccination with necroptotic cancer cells
induces efficient anti-tumor immunity. Cell Rep. 15:274–287.
2016.
|
|
51
|
Krysko DV, Garg AD, Kaczmarek A, Krysko O,
Agostinis P and Vandenabeele P: Immunogenic cell death and DAMPs in
cancer therapy. Nat Rev Cancer. 12:860–875. 2012.
|
|
52
|
Davola ME, Cormier O, Vito A, El-Sayes N,
Collins S, Salem O, Revill S, Ask K, Wan Y and Mossman K: Oncolytic
BHV-1 is sufficient to induce immunogenic cell death and synergizes
with low-dose chemotherapy to dampen immunosuppressive T regulatory
cells. Cancers (Basel). 15:12952023.
|
|
53
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012.
|
|
54
|
Tang D, Chen X, Kang R and Kroemer G:
Ferroptosis: Molecular mechanisms and health implications. Cell
Res. 31:107–125. 2021.
|
|
55
|
Friedmann Angeli JP, Schneider M, Proneth
B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch
A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator
Gpx4 triggers acute renal failure in mice. Nat Cell Biol.
16:1180–1191. 2014.
|
|
56
|
Doll S, Proneth B, Tyurina YY, Panzilius
E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A,
et al: ACSL4 dictates ferroptosis sensitivity by shaping cellular
lipid composition. Nat Chem Biol. 13:91–98. 2017.
|
|
57
|
Stockwell BR: Ferroptosis turns 10:
Emerging mechanisms, physiological functions, and therapeutic
applications. Cell. 185:2401–2421. 2022.
|
|
58
|
Stockwell BR, Jiang X and Gu W: Emerging
mechanisms and disease relevance of ferroptosis. Trends Cell Biol.
30:478–490. 2020.
|
|
59
|
Shah R, Shchepinov MS and Pratt DA:
Resolving the role of lipoxygenases in the initiation and execution
of ferroptosis. ACS Central Sci. 4:387–396. 2018.
|
|
60
|
Patel SJ, Protchenko O, Shakoury-Elizeh M,
Baratz E, Jadhav S and Philpott CC: The iron chaperone and nucleic
acid-binding activities of poly(rC)-binding protein 1 are separable
and independently essential. Proc Natl Acad Sci USA.
118:e21046661182021.
|
|
61
|
Bloomer SA and Brown KE: Hepcidin and iron
metabolism in experimental liver injury. Am J Pathol.
191:1165–1179. 2021.
|
|
62
|
Zhang HL, Hu BX, Li ZL, Du T, Shan JL, Ye
ZP, Peng XD, Li X, Huang Y, Zhu XY, et al: PKCβII phosphorylates
ACSL4 to amplify lipid peroxidation to induce ferroptosis. Nat Cell
Biol. 24:88–98. 2022.
|
|
63
|
Zou Y, Li H, Graham ET, Deik AA, Eaton JK,
Wang W, Sandoval-Gomez G, Clish CB, Doench JG and Schreiber SL:
Cytochrome P450 oxidoreductase contributes to phospholipid
peroxidation in ferroptosis. Nat Chem Biol. 16:302–309. 2020.
|
|
64
|
Shimada K, Skouta R, Kaplan A, Yang WS,
Hayano M, Dixon SJ, Brown LM, Valenzuela CA, Wolpaw AJ and
Stockwell BR: Global survey of cell death mechanisms reveals
metabolic regulation of ferroptosis. Nat Chem Biol. 12:497–503.
2016.
|
|
65
|
Hassannia B, Vandenabeele P and Vanden
Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell.
35:830–849. 2019.
|
|
66
|
Cao JY, Poddar A, Magtanong L, Lumb JH,
Mileur TR, Reid MA, Dovey CM, Wang J, Locasale JW, Stone E, et al:
A genome-wide haploid genetic screen identifies regulators of
glutathione abundance and ferroptosis sensitivity. Cell Rep.
26:1544–1556.e8. 2019.
|
|
67
|
Hao S, Yu J, He W, Huang Q, Zhao Y, Liang
B, Zhang S, Wen Z, Dong S, Rao J, et al: Cysteine dioxygenase 1
mediates erastin-induced ferroptosis in human gastric cancer cells.
Neoplasia. 19:1022–1032. 2017.
|
|
68
|
Bersuker K, Hendricks JM, Li Z, Magtanong
L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al:
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit
ferroptosis. Nature. 575:688–692. 2019.
|
|
69
|
Mao C, Liu X, Zhang Y, Lei G, Yan Y, Lee
H, Koppula P, Wu S, Zhuang L, Fang B, et al: DHODH-mediated
ferroptosis defence is a targetable vulnerability in cancer.
Nature. 593:586–590. 2021.
|
|
70
|
Liu Y, Lu S, Wu LL, Yang L, Yang L and
Wang J: The diversified role of mitochondria in ferroptosis in
cancer. Cell Death Dis. 14:5192023.
|
|
71
|
Gao M, Yi J, Zhu J, Minikes AM, Monian P,
Thompson CB and Jiang X: Role of mitochondria in ferroptosis. Mol
Cell. 73:354–363.e3. 2019.
|
|
72
|
Jiang L, Kon N, Li T, Wang SJ, Su T,
Hibshoosh H, Baer R and Gu W: Ferroptosis as a p53-mediated
activity during tumour suppression. Nature. 520:57–62. 2015.
|
|
73
|
Kraft VAN, Bezjian CT, Pfeiffer S,
Ringelstetter L, Müller C, Zandkarimi F, Merl-Pham J, Bao X,
Anastasov N, Kössl J, et al: GTP cyclohydrolase
1/tetrahydrobiopterin counteract ferroptosis through lipid
remodeling. ACS Central Sci. 6:41–53. 2020.
|
|
74
|
Soula M, Weber RA, Zilka O, Alwaseem H, La
K, Yen F, Molina H, Garcia-Bermudez J, Pratt DA and Birsoy K:
Metabolic determinants of cancer cell sensitivity to canonical
ferroptosis inducers. Nat Chem Biol. 16:1351–1360. 2020.
|
|
75
|
Zeitler L, Fiore A, Meyer C, Russier M,
Zanella G, Suppmann S, Gargaro M, Sidhu SS, Seshagiri S, Ohnmacht
C, et al: Anti-ferroptotic mechanism of IL4i1-mediated amino acid
metabolism. Elife. 10:e648062021.
|
|
76
|
Shi J, Zhao Y, Wang K, Shi X, Wang Y,
Huang H, Zhuang Y, Cai T, Wang F and Shao F: Cleavage of GSDMD by
inflammatory caspases determines pyroptotic cell death. Nature.
526:660–665. 2015.
|
|
77
|
Cookson BT and Brennan MA:
Pro-inflammatory programmed cell death. Trends Microbiol.
9:113–114. 2001.
|
|
78
|
Hou J, Hsu JM and Hung MC: Molecular
mechanisms and functions of pyroptosis in inflammation and
antitumor immunity. Mol Cell. 81:4579–4590. 2021.
|
|
79
|
Liu Z, Wang C, Yang J, Zhou B, Yang R,
Ramachandran R, Abbott DW and Xiao TS: Crystal structures of the
full-length murine and human gasdermin D reveal mechanisms of
autoinhibition, lipid binding, and oligomerization. Immunity.
51:43–49.e4. 2019.
|
|
80
|
Ding J, Wang K, Liu W, She Y, Sun Q, Shi
J, Sun H, Wang DC and Shao F: Pore-forming activity and structural
autoinhibition of the gasdermin family. Nature. 535:111–116.
2016.
|
|
81
|
Liu X, Zhang Z, Ruan J, Pan Y, Magupalli
VG, Wu H and Lieberman J: Inflammasome-activated gasdermin D causes
pyroptosis by forming membrane pores. Nature. 535:153–158.
2016.
|
|
82
|
Aglietti RA and Dueber EC: Recent insights
into the molecular mechanisms underlying pyroptosis and gasdermin
family functions. Trends Immunol. 38:261–271. 2017.
|
|
83
|
Fink SL and Cookson BT: Pillars article:
Caspase-1-dependent pore formation during pyroptosis leads to
osmotic lysis of infected host macrophages. Cell Microbiol.
2006.8:1812–1825
J Immunol. 202:1913–1926. 2019.
|
|
84
|
Kayagaki N, Stowe IB, Lee BL, O'Rourke K,
Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT,
et al: Caspase-11 cleaves gasdermin D for non-canonical
inflammasome signalling. Nature. 526:666–671. 2015.
|
|
85
|
Kayagaki N, Warming S, Lamkanfi M, Vande
Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, et al:
Non-canonical inflammasome activation targets caspase-11. Nature.
479:117–121. 2011.
|
|
86
|
Yang D, He Y, Muñoz-Planillo R, Liu Q and
Núñez G: Caspase-11 requires the pannexin-1 channel and the
purinergic P2X7 pore to mediate pyroptosis and endotoxic shock.
Immunity. 43:923–932. 2015.
|
|
87
|
Wang Y, Gao W, Shi X, Ding J, Liu W, He H,
Wang K and Shao F: Chemotherapy drugs induce pyroptosis through
caspase-3 cleavage of a gasdermin. Nature. 547:99–103. 2017.
|
|
88
|
Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu
JM, Nie L, Chen Y, Wang YC, Liu C, et al: PD-L1-mediated gasdermin
C expression switches apoptosis to pyroptosis in cancer cells and
facilitates tumour necrosis. Nat Cell Biol. 22:1264–1275. 2020.
|
|
89
|
Rogers C, Fernandes-Alnemri T, Mayes L,
Alnemri D, Cingolani G and Alnemri ES: Cleavage of DFNA5 by
caspase-3 during apoptosis mediates progression to secondary
necrotic/pyroptotic cell death. Nat Commun. 8:141282017.
|
|
90
|
Orning P, Weng D, Starheim K, Ratner D,
Best Z, Lee B, Brooks A, Xia S, Wu H, Kelliher MA, et al: Pathogen
blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin
D and cell death. Science. 362:1064–1069. 2018.
|
|
91
|
Sarhan J, Liu BC, Muendlein HI, Li P,
Nilson R, Tang AY, Rongvaux A, Bunnell SC, Shao F, Green DR and
Poltorak A: Caspase-8 induces cleavage of gasdermin D to elicit
pyroptosis during Yersinia infection. Proc Natl Acad Sci USA.
115:E10888–E10897. 2018.
|
|
92
|
Liu Y, Fang Y, Chen X, Wang Z, Liang X,
Zhang T, Liu M, Zhou N, Lv J, Tang K, et al: Gasdermin E-mediated
target cell pyroptosis by CAR T cells triggers cytokine release
syndrome. Sci Immunol. 5:eaax79692020.
|
|
93
|
Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu
X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, et al: Gasdermin E
suppresses tumour growth by activating anti-tumour immunity.
Nature. 579:415–420. 2020.
|
|
94
|
Erkes DA, Cai W, Sanchez IM, Purwin TJ,
Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES
and Aplin AE: Mutant BRAF and MEK inhibitors regulate the tumor
immune microenvironment via pyroptosis. Cancer Discov. 10:254–269.
2020.
|
|
95
|
Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y,
Wang Y, Li D, Liu W, Zhang Y, et al: Granzyme A from cytotoxic
lymphocytes cleaves GSDMB to trigger pyroptosis in target cells.
Science. 368:eaaz75482020.
|
|
96
|
Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li
P, Hu L and Shao F: Inflammatory caspases are innate immune
receptors for intracellular LPS. Nature. 514:187–192. 2014.
|
|
97
|
Deets KA and Vance RE: Inflammasomes and
adaptive immune responses. Nat Immunol. 22:412–422. 2021.
|
|
98
|
Guo H, Callaway JB and Ting JP:
Inflammasomes: Mechanism of action, role in disease, and
therapeutics. Nat Med. 21:677–687. 2015.
|
|
99
|
Wang K, Sun Q, Zhong X, Zeng M, Zeng H,
Shi X, Li Z, Wang Y, Zhao Q, Shao F and Ding J: Structural
mechanism for GSDMD targeting by autoprocessed caspases in
pyroptosis. Cell. 180:941–955.e20. 2020.
|
|
100
|
Loveless R, Bloomquist R and Teng Y:
Pyroptosis at the forefront of anticancer immunity. J Exp Clin Canc
Res. 40:2642021.
|
|
101
|
Degterev A, Huang Z, Boyce M, Li Y, Jagtap
P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA and Yuan J:
Chemical inhibitor of nonapoptotic cell death with therapeutic
potential for ischemic brain injury. Nat Chem Biol. 1:112–119.
2005.
|
|
102
|
Frank D and Vince JE: Pyroptosis versus
necroptosis: Similarities, differences, and crosstalk. Cell Death
Differ. 26:99–114. 2019.
|
|
103
|
Choi ME, Price DR, Ryter SW and Choi AMK:
Necroptosis: A crucial pathogenic mediator of human disease. JCI
Insight. 4:e1288342019.
|
|
104
|
Lork M, Verhelst K and Beyaert R: CYLD,
A20 and OTULIN deubiquitinases in NF-κB signaling and cell death:
So similar, yet so different. Cell Death Differ. 24:1172–1183.
2017.
|
|
105
|
Priem D, van Loo G and Bertrand MJM: A20
and cell death-driven inflammation. Trends Immunol. 41:421–435.
2020.
|
|
106
|
Ye K, Chen Z and Xu Y: The double-edged
functions of necroptosis. Cell Death Dis. 14:1632023.
|
|
107
|
Feoktistova M, Geserick P, Kellert B,
Dimitrova DP, Langlais C, Hupe M, Cain K, MacFarlane M, Häcker G
and Leverkus M: cIAPs block Ripoptosome formation, a RIP1/caspase-8
containing intracellular cell death complex differentially
regulated by cFLIP isoforms. Mol Cell. 43:449–463. 2011.
|
|
108
|
Mompeán M, Li W, Li J, Laage S, Siemer AB,
Bozkurt G, Wu H and McDermott AE: The structure of the necrosome
RIPK1-RIPK3 core, a human hetero-amyloid signaling complex. Cell.
173:1244–1253.e10. 2018.
|
|
109
|
Sun L, Wang H, Wang Z, He S, Chen S, Liao
D, Wang L, Yan J, Liu W, Lei X and Wang X: Mixed lineage kinase
domain-like protein mediates necrosis signaling downstream of RIP3
kinase. Cell. 148:213–227. 2012.
|
|
110
|
Kaczmarek A, Vandenabeele P and Krysko DV:
Necroptosis: The release of damage-associated molecular patterns
and its physiological relevance. Immunity. 38:209–223. 2013.
|
|
111
|
Kaiser WJ, Sridharan H, Huang C, Mandal P,
Upton JW, Gough PJ, Sehon CA, Marquis RW, Bertin J and Mocarski ES:
Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J
Biol Chem. 288:31268–31279. 2013.
|
|
112
|
Zhang W, Fan W, Guo J and Wang X: Osmotic
stress activates RIPK3/MLKL-mediated necroptosis by increasing
cytosolic pH through a plasma membrane Na+/H+
exchanger. Sci Signal. 15:eabn58812022.
|
|
113
|
Coriat R, Nicco C, Chéreau C, Mir O,
Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F and
Batteux F: Sorafenib-induced hepatocellular carcinoma cell death
depends on reactive oxygen species production in vitro and in vivo.
Mol Cancer Ther. 11:2284–2293. 2012.
|
|
114
|
Louandre C, Ezzoukhry Z, Godin C, Barbare
JC, Mazière JC, Chauffert B and Galmiche A: Iron-dependent cell
death of hepatocellular carcinoma cells exposed to sorafenib. Int J
Cancer. 133:1732–1742. 2013.
|
|
115
|
Huang CY, Chen LJ, Chen G, Chao TI and
Wang CY: SHP-1/STAT3-signaling-axis-regulated coupling between
BECN1 and SLC7A11 contributes to sorafenib-induced ferroptosis in
hepatocellular carcinoma. Int J Mol Sci. 23:110922022.
|
|
116
|
Suzuki S, Venkatesh D, Kanda H, Nakayama
A, Hosokawa H, Lee E, Miki T, Stockwell BR, Yokote K, Tanaka T and
Prives C: GLS2 is a tumor suppressor and a regulator of ferroptosis
in hepatocellular carcinoma. Cancer Res. 82:3209–3222. 2022.
|
|
117
|
Chen Y, Li L, Lan J, Cui Y, Rao X, Zhao J,
Xing T, Ju G, Song G, Lou J and Liang J: CRISPR screens uncover
protective effect of PSTK as a regulator of chemotherapy-induced
ferroptosis in hepatocellular carcinoma. Mol Cancer. 21:112022.
|
|
118
|
Zhang B, Bao W, Zhang S, Chen B, Zhou X,
Zhao J, Shi Z, Zhang T, Chen Z, Wang L, et al: LncRNA HEPFAL
accelerates ferroptosis in hepatocellular carcinoma by regulating
SLC7A11 ubiquitination. Cell Death Dis. 13:7342022.
|
|
119
|
Chen Q, Zheng W, Guan J, Liu H, Dan Y, Zhu
L, Song Y, Zhou Y, Zhao X, Zhang Y, et al: SOCS2-enhanced
ubiquitination of SLC7A11 promotes ferroptosis and
radiosensitization in hepatocellular carcinoma. Cell Death Differ.
30:137–151. 2023.
|
|
120
|
Du J, Wan Z, Wang C, Lu F, Wei M, Wang D
and Hao Q: Designer exosomes for targeted and efficient ferroptosis
induction in cancer via chemo-photodynamic therapy. Theranostics.
11:8185–8196. 2021.
|
|
121
|
Liu J, Li X, Chen J, Zhang X, Guo J, Gu J,
Mei C, Xiao Y, Peng C, Liu J, et al: Arsenic-loaded biomimetic iron
oxide nanoparticles for enhanced ferroptosis-inducing therapy of
hepatocellular carcinoma. ACS Appl Mater Interfaces. 15:6260–6273.
2023.
|
|
122
|
Tian H, Zhao S, Nice EC, Huang C, He W,
Zou B and Lin J: A cascaded copper-based nanocatalyst by modulating
glutathione and cyclooxygenase-2 for hepatocellular carcinoma
therapy. J Colloid Interface Sci. 607:1516–1526. 2022.
|
|
123
|
Su Y, Zhang Z, Lee LTO, Peng L, Lu L, He X
and Zhang X: Amphiphilic dendrimer doping enhanced ph-sensitivity
of liposomal vesicle for effective co-delivery toward synergistic
ferroptosis-apoptosis therapy of hepatocellular carcinoma. Adv
Healthc Mater. 12:e22026632023.
|
|
124
|
Zhang Z, Yao Z, Wang L, Ding H, Shao J,
Chen A, Zhang F and Zheng S: Activation of ferritinophagy is
required for the RNA-binding protein ELAVL1/HuR to regulate
ferroptosis in hepatic stellate cells. Autophagy. 14:2083–2103.
2018.
|
|
125
|
Zhang Z, Guo M, Li Y, Shen M, Kong D, Shao
J, Ding H, Tan S, Chen A, Zhang F and Zheng S: RNA-binding protein
ZFP36/TTP protects against ferroptosis by regulating autophagy
signaling pathway in hepatic stellate cells. Autophagy.
16:1482–1505. 2020.
|
|
126
|
Tsuchida T and Friedman SL: Mechanisms of
hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol.
14:397–411. 2017.
|
|
127
|
Shen M, Li Y, Wang Y, Shao J, Zhang F, Yin
G, Chen A, Zhang Z and Zheng S: N6-methyladenosine
modification regulates ferroptosis through autophagy signaling
pathway in hepatic stellate cells. Redox Biol. 47:1021512021.
|
|
128
|
Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH,
Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, et al: Artesunate
synergizes with sorafenib to induce ferroptosis in hepatocellular
carcinoma. Acta Pharmacol Sin. 42:301–310. 2021.
|
|
129
|
Sun X, Niu X, Chen R, He W, Chen D, Kang R
and Tang D: Metallothionein-1G facilitates sorafenib resistance
through inhibition of ferroptosis. Hepatology. 64:488–500.
2016.
|
|
130
|
Byun JK, Lee S, Kang GW, Lee YR, Park SY,
Song IS, Yun JW, Lee J, Choi YK and Park KG: Macropinocytosis is an
alternative pathway of cysteine acquisition and mitigates
sorafenib-induced ferroptosis in hepatocellular carcinoma. J Exp
Clin Cancer Res. 41:982022.
|
|
131
|
Byun JK: Tumor lactic acid: A potential
target for cancer therapy. Arch Pharm Res. 46:90–110. 2023.
|
|
132
|
Zhang T, Sun L, Hao Y, Suo C, Shen S, Wei
H, Ma W, Zhang P, Wang T, Gu X, et al: ENO1 suppresses cancer cell
ferroptosis by degrading the mRNA of iron regulatory protein 1. Nat
Cancer. 3:75–89. 2022.
|
|
133
|
Zhao Y, Li M, Yao X, Fei Y, Lin Z, Li Z,
Cai K, Zhao Y and Luo Z: HCAR1/MCT1 regulates tumor ferroptosis
through the lactate-mediated AMPK-SCD1 activity and its therapeutic
implications. Cell Rep. 33:1084872020.
|
|
134
|
Yang Z, Su W, Wei X, Qu S, Zhao D, Zhou J,
Wang Y, Guan Q, Qin C, Xiang J, et al: HIF-1α drives resistance to
ferroptosis in solid tumors by promoting lactate production and
activating SLC1A1. Cell Rep. 42:1129452023.
|
|
135
|
Ma Q: Role of nrf2 in oxidative stress and
toxicity. Annu Rev Pharmacol Toxicol. 53:401–426. 2013.
|
|
136
|
Sporn MB and Liby KT: NRF2 and cancer: The
good, the bad and the importance of context. Nat Rev Cancer.
12:564–571. 2012.
|
|
137
|
Ichimura Y, Waguri S, Sou YS, Kageyama S,
Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, et
al: Phosphorylation of p62 activates the Keap1-Nrf2 pathway during
selective autophagy. Mol Cell. 51:618–631. 2013.
|
|
138
|
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R
and Tang D: Activation of the p62-Keap1-NRF2 pathway protects
against ferroptosis in hepatocellular carcinoma cells. Hepatology.
63:173–184. 2016.
|
|
139
|
Ren X, Li Y, Zhou Y, Hu W, Yang C, Jing Q,
Zhou C, Wang X, Hu J, Wang L, et al: Overcoming the compensatory
elevation of NRF2 renders hepatocellular carcinoma cells more
vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol.
46:1021222021.
|
|
140
|
Wang Q, Bin C, Xue Q, Gao Q, Huang A, Wang
K and Tang N: GSTZ1 sensitizes hepatocellular carcinoma cells to
sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Cell Death Dis. 12:4262021.
|
|
141
|
Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu
X, Martinez C, Su X, Rosato RR, Teng H, et al: A targetable
LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability
to ferroptosis. Nat Commun. 12:73332021.
|
|
142
|
Hu J, Dong Y, Ding L, Dong Y, Wu Z, Wang
W, Shen M and Duan Y: Local delivery of arsenic trioxide
nanoparticles for hepatocellular carcinoma treatment. Signal
Transduct Target Ther. 4:282019.
|
|
143
|
Shangguan F, Zhou H, Ma N, Wu S, Huang H,
Jin G, Wu S, Hong W, Zhuang W, Xia H and Lan L: A novel mechanism
of cannabidiol in suppressing hepatocellular carcinoma by inducing
GSDME dependent pyroptosis. Front Cell Dev Biol. 9:6978322021.
|
|
144
|
Dai X, Sun F, Deng K, Lin G, Yin W, Chen
H, Yang D, Liu K, Zhang Y and Huang L: Mallotucin D, a clerodane
diterpenoid from croton crassifolius, suppresses HepG2 cell growth
via inducing autophagic cell death and pyroptosis. Int J Mol Sci.
23:142172022.
|
|
145
|
Shen Z, Zhou H, Li A, Wu T, Ji X, Guo L,
Zhu X, Zhang D and He X: Metformin inhibits hepatocellular
carcinoma development by inducing apoptosis and pyroptosis through
regulating FOXO3. Aging (Albany NY). 13:22120–22133. 2021.
|
|
146
|
Chen Z, He M, Chen J, Li C and Zhang Q:
Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by
targeting the miR-34a/SIRT1 axis in liver cancer. Oncol Lett.
20:893–901. 2020.
|
|
147
|
Kofahi HM, Taylor NGA, Hirasawa K, Grant
MD and Russell RS: Hepatitis C virus infection of cultured human
hepatoma cells causes apoptosis and pyroptosis in both infected and
bystander cells. Sci Rep. 6:374332016.
|
|
148
|
Wei Q, Zhu R, Zhu J, Zhao R and Li M:
E2-induced activation of the NLRP3 inflammasome triggers pyroptosis
and inhibits autophagy in HCC cells. Oncol Res. 27:827–834.
2019.
|
|
149
|
Zhang Y, Yang H, Sun M, He T, Liu Y, Yang
X, Shi X and Liu X: Alpinumisoflavone suppresses hepatocellular
carcinoma cell growth and metastasis via NLRP3
inflammasome-mediated pyroptosis. Pharmacol Rep. 72:1370–1382.
2020.
|
|
150
|
Wang F, Xu C, Li G, Lv P and Gu J:
Incomplete radiofrequency ablation induced chemoresistance by
up-regulating heat shock protein 70 in hepatocellular carcinoma.
Exp Cell Res. 409:1129102021.
|
|
151
|
Seehawer M, Heinzmann F, D'Artista L,
Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G,
et al: Necroptosis microenvironment directs lineage commitment in
liver cancer. Nature. 562:69–75. 2018.
|
|
152
|
Schneider AT, Gautheron J, Feoktistova M,
Roderburg C, Loosen SH, Roy S, Benz F, Schemmer P, Büchler MW,
Nachbur U, et al: RIPK1 suppresses a TRAF2-dependent pathway to
liver cancer. Cancer Cell. 31:94–109. 2017.
|
|
153
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer.
12:862013.
|
|
154
|
Jomen W, Ohtake T, Akita T, Suto D, Yagi
H, Osawa Y and Kohgo Y: Iron chelator deferasirox inhibits NF-κB
activity in hepatoma cells and changes sorafenib-induced programmed
cell deaths. Biomed Pharmacother. 153:1133632022.
|
|
155
|
Harari-Steinfeld R, Gefen M, Simerzin A,
Zorde-Khvalevsky E, Rivkin M, Ella E, Friehmann T, Gerlic M,
Zucman-Rossi J, Caruso S, et al: The lncRNA H19-derived
MicroRNA-675 promotes liver necroptosis by targeting FADD. Cancers
(Basel). 13:4112021.
|
|
156
|
Zheng Y, Kong F, Liu S, Liu X, Pei D and
Miao X: Membrane protein-chimeric liposome-mediated delivery of
triptolide for targeted hepatocellular carcinoma therapy. Drug
Deliv. 28:2033–2043. 2021.
|
|
157
|
Mohammed S, Thadathil N, Selvarani R,
Nicklas EH, Wang D, Miller BF, Richardson A and Deepa SS:
Necroptosis contributes to chronic inflammation and fibrosis in
aging liver. Aging Cell. 20:e135122021.
|
|
158
|
Hammerich L and Tacke F: Eat more carrots?
Dampening cell death in ethanol-induced liver fibrosis by
β-carotene. Hepatobil Surg Nutr. 2:248–251. 2013.
|
|
159
|
Zhao B, Lv X, Zhao X, Maimaitiaili S,
Zhang Y, Su K, Yu H, Liu C and Qiao T: Tumor-promoting actions of
HNRNP A1 in HCC are associated with cell cycle, mitochondrial
dynamics, and necroptosis. Int J Mol Sci. 23:102092022.
|
|
160
|
Lee SY, Kim S, Song Y, Kim N, No J, Kim KM
and Seo HR: Sorbitol dehydrogenase induction of cancer cell
necroptosis and macrophage polarization in the HCC microenvironment
suppresses tumor progression. Cancer Lett. 551:2159602022.
|
|
161
|
Lan W, Santofimia-Castaño P, Xia Y, Zhou
Z, Huang C, Fraunhoffer N, Barea D, Cervello M, Giannitrapani L,
Montalto G, et al: Targeting NUPR1 with the small compound ZZW-115
is an efficient strategy to treat hepatocellular carcinoma. Cancer
Lett. 486:8–17. 2020.
|
|
162
|
Tran DDH, Kessler C, Niehus SE, Mahnkopf
M, Koch A and Tamura T: Myc target gene, long intergenic noncoding
RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and
cell survival by titrating tumor suppressor microRNAs. Oncogene.
37:75–85. 2018.
|
|
163
|
Xiang YK, Peng FH, Guo YQ, Ge H, Cai SY,
Fan LX, Peng YX, Wen H, Wang Q and Tao L: Connexin32 activates
necroptosis through Src-mediated inhibition of caspase 8 in
hepatocellular carcinoma. Cancer Sci. 112:3507–3519. 2021.
|
|
164
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al:
CD8+ T cells regulate tumour ferroptosis during cancer
immunotherapy. Nature. 569:270–274. 2019.
|
|
165
|
Xi G, Gao J, Wan B, Zhan P, Xu W, Lv T and
Song Y: GSDMD is required for effector CD8+ T cell
responses to lung cancer cells. Int Immunopharmacol.
74:1057132019.
|
|
166
|
Yatim N, Jusforgues-Saklani H, Orozco S,
Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst A
and Albert ML: RIPK1 and NF-κB signaling in dying cells determines
cross-priming of CD8+ T cells. Science. 350:328–334. 2015.
|
|
167
|
Kang T, Huang Y, Zhu Q, Cheng H, Pei Y,
Feng J, Xu M, Jiang G, Song Q, Jiang T, et al: Necroptotic cancer
cells-mimicry nanovaccine boosts anti-tumor immunity with tailored
immune-stimulatory modality. Biomaterials. 164:80–97. 2018.
|
|
168
|
Snyder AG, Hubbard NW, Messmer MN, Kofman
SB, Hagan CE, Orozco SL, Chiang K, Daniels BP, Baker D and Oberst
A: Intratumoral activation of the necroptotic pathway components
RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol.
4:eaaw20042019.
|
|
169
|
Galluzzi L, Buqué A, Kepp O, Zitvogel L
and Kroemer G: Immunogenic cell death in cancer and infectious
disease. Nat Rev Immunol. 17:97–111. 2017.
|
|
170
|
Conche C, Finkelmeier F, Pešić M, Nicolas
AM, Böttger TW, Kennel KB, Denk D, Ceteci F, Mohs K, Engel E, et
al: Combining ferroptosis induction with MDSC blockade renders
primary tumours and metastases in liver sensitive to immune
checkpoint blockade. Gut. 72:1774–1782. 2023.
|
|
171
|
Li S, Li F, Xu L, Liu X, Zhu X, Gao W and
Shen X: TLR2 agonist promotes myeloid-derived suppressor cell
polarization via Runx1 in hepatocellular carcinoma. Int
Immunopharmacol. 111:1091682022.
|
|
172
|
Li Z, Wu T, Zheng B and Chen L:
Individualized precision treatment: Targeting TAM in HCC. Cancer
Lett. 458:86–91. 2019.
|
|
173
|
Loeuillard E, Yang J, Buckarma E, Wang J,
Liu Y, Conboy C, Pavelko KD, Li Y, O'Brien D, Wang C, et al:
Targeting tumor-associated macrophages and granulocytic
myeloid-derived suppressor cells augments PD-1 blockade in
cholangiocarcinoma. J Clin Invest. 130:5380–5396. 2020.
|
|
174
|
DeNardo DG and Ruffell B: Macrophages as
regulators of tumour immunity and immunotherapy. Nat rev immunol.
19:369–382. 2019.
|
|
175
|
Farhood B, Najafi M and Mortezaee K:
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A
review. J Cell Physiol. 234:8509–8521. 2019.
|
|
176
|
Hao X, Zheng Z, Liu H, Zhang Y, Kang J,
Kong X, Rong D, Sun G, Sun G, Liu L, et al: Inhibition of APOC1
promotes the transformation of M2 into M1 macrophages via the
ferroptosis pathway and enhances anti-PD1 immunotherapy in
hepatocellular carcinoma based on single-cell RNA sequencing. Redox
Biol. 56:1024632022.
|
|
177
|
Chen R, Li Q, Xu S, Ye C, Tian T, Jiang Q,
Shan J and Ruan J: Modulation of the tumour microenvironment in
hepatocellular carcinoma by tyrosine kinase inhibitors: From
modulation to combination therapy targeting the microenvironment.
Cancer Cell Int. 22:732022.
|
|
178
|
Li J, Yu J, Zhang T, Pu X, Li Y and Wu Z:
Genomic analysis quantifies pyroptosis in the immune
microenvironment of HBV-related hepatocellular carcinoma. Front
immunol. 13:9323032022.
|
|
179
|
Mohammed S, Nicklas EH, Thadathil N,
Selvarani R, Royce GH, Kinter M, Richardson A and Deepa SS: Role of
necroptosis in chronic hepatic inflammation and fibrosis in a mouse
model of increased oxidative stress. Free Radical Bio Med.
164:315–328. 2021.
|
|
180
|
Tang D, Kang R, Berghe TV, Vandenabeele P
and Kroemer G: The molecular machinery of regulated cell death.
Cell Res. 29:347–364. 2019.
|
|
181
|
Jiang X, Deng W, Tao S, Tang Z, Chen Y,
Tian M, Wang T, Tao C, Li Y, Fang Y, et al: A RIPK3-independent
role of MLKL in suppressing parthanatos promotes immune evasion in
hepatocellular carcinoma. Cell Discov. 9:72023.
|
|
182
|
Wu L, Zhang X, Zheng L, Zhao H, Yan G,
Zhang Q, Zhou Y, Lei J, Zhang J, Wang J, et al: RIPK3 orchestrates
fatty acid metabolism in tumor-associated macrophages and
hepatocarcinogenesis. Cancer Immunol Res. 8:710–721. 2020.
|
|
183
|
Nicolè L, Sanavia T, Cappellesso R,
Maffeis V, Akiba J, Kawahara A, Naito Y, Radu CM, Simioni P,
Serafin D, et al: Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p
are associated with intratumoral CD3+ and
CD8+ T cell density and predict prognosis in
hepatocellular carcinoma. J Immunother Cancer. 10:e0040312022.
|
|
184
|
Pomlok K, Pata S, Kulaphisit M, Pangnuchar
R, Wipasa J, Smith DR, Kasinrerk W and Lithanatudom P: An IgM
monoclonal antibody against domain 1 of CD147 induces non-canonical
RIPK-independent necroptosis in a cell type specific manner in
hepatocellular carcinoma cells. Biochim Biophys Acta Mol Cell Res.
1869:1192952022.
|
